Trulicity dulaglutide patent expiration biosimilar?

Short answer:
- There are no FDA-approved dulaglutide (Trulicity) biosimilars as of now.
- Trulicity is protected by multiple patents (covering the active molecule, formulations, and methods of use) plus biologic data exclusivity. Because these patent protections are in multiple families with different expiry dates, there isn’t a single expiration date. In the U.S., the regulatory data exclusivity for a biologic is 12 years from approval, which often delays biosimilar entry even after patents expire.
- Patent expiry dates vary by country and patent family, and some patents can be extended or litigated, so the earliest potential biosimilar entry is not fixed and could be several years after the last core patent expires.

What you might want to check for current status
- U.S. patents and exclusivity: FDA Orange Book listings for dulaglutide (Trulicity) patents and any exclusivity notes.
- European status: EU patent coverage and any regulatory exclusivity details.
- Biosimilar developers and progress: public announcements from companies (e.g., in preclinical/clinical development) and any regulatory submissions or approvals.

If you tell me which region you care about (U.S., EU, or elsewhere), I can outline the latest known status and where to check for updates. I can also help look up current patent and biosimilar development status if you’d like.